LIGHT: A Novel Immunotherapy for Primary and Metastatic Prostate Cancer
Annual rept. 1 Sep 2012-31 Aug 2013
UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
Pagination or Media Count:
Over-expression of LIGHT has been show in various tumor models to induce tumor regression and tumor immunogencity. However, the models are based on transplanted tumors that express artificial foreign antigens that function as tumor antigens, LIGHT has never been evaluated in prostate cancer, where self-antigens likely exist. We have provided the first evidence that LIGHT-induced T cells are specific for at least one relevant prostate expressed self-antigen, PSCA. We have also demonstrated that LIGHT treatment in prostate cancer has a positive effect on the tumor microenvironment, which suggests a strong likelihood that combination treatment with LIGHT and immunotherapeutic vaccination will have an impact against primary and possibly metastatic prostate cancer. Thus, therapeutic intervention by delivering LIGHT to the tumors may serve the dual purpose of inhibiting immune-suppression mediated by regulatory T cells while simultaneously activating tumor-specific immune responses, which we hope to demonstrate can be boosted by vaccination. This study may potentially provide a practical means of overcoming tumor-mediated immunosuppressive mechanisms in a variety of solid human tumors, including those of the prostate, which would have important implications for patients who are diagnosed at the later stages of disease and currently have no recourse for treatment.
- Medicine and Medical Research